Hyperhomocyst(e)inemia impairs angiogenesis in a murine model of limb ischemia

Vascular Medicine

Volumn 10, Issue 1, 2005, Pages 15-22

  Bosch Marcé, Marta ^a   Pola, Roberto ^a   Wecker, Andrea B ^a   Silver, Marcy ^a   Weber, Alberto ^a   Luedemann, Corinne ^a   Curry, Cynthia ^a   Murayama, Toshinori ^a   Kearney, Marianne ^a   Yoon, Young Sup ^a   Malinow, M René ^b   Asahara, Takayuki ^a   Isner, Jeffrey M ^a   Losordo, Douglas W ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Akt; Angiogenesis; Flk 1; Hyperhomocyst(e)inemia; Ischemia; VEGF

Indexed keywords

CYSTATHIONINE BETA SYNTHASE; HOMOCYSTEINE; PROTEIN KINASE B; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; GENE DELETION; GENETIC ENGINEERING; HETEROZYGOTE; HINDLIMB; HUMAN; HUMAN CELL; HYPERHOMOCYSTEINEMIA; IN VITRO STUDY; LASER DOPPLER FLOWMETRY; LEG MUSCLE; LIMB BLOOD FLOW; LIMB ISCHEMIA; LIMB PERFUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STATISTICAL SIGNIFICANCE; UMBILICAL VEIN;

ANIMALS; DISEASE MODELS, ANIMAL; HYPERHOMOCYSTEINEMIA; ISCHEMIA; MICE; MICE, INBRED STRAINS; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 20844444142     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x05vm585oa     Document Type: Article

References (54)

1. Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999; 19: 217-46.
2. Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993; 71: 337-59.
3. Harker LA, Harlan JM, Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res 1983; 53: 731-39.
4. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980; 18: 113-21.
5. Bellamy MF, McDowell IF. Putative mechanisms for vascular damage by homocysteine. J Inherit Metab Dis 1997; 20: 307-15.
6. Lee HY, Chae IH, Kim HS et al. Differential effects of homocysteine on porcine endothelial and vascular smooth muscle cells. J Cardiovasc Pharmacol 2002; 39: 643-51.
7. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999; 131: 363-75.
8. Clarke R, Daly L, Robinson K et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
9. Eberhardt RT, Forgione MA, Cap A et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 2000; 106: 483-91.
10. McDowell IF, Lang D. Homocysteine and endothelial dysfunction: a link with cardiovascular disease. J Nutr 2000; 130: 369S-72S.
11. Wang H, Yoshizumi M, Lai K et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997; 272: 25380-85.
12. Tsai JC, Perrella MA, Yoshizumi M et al. Promotion of vascular smooth muscle cell growth by Homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 1994; 91: 6369-73.
13. Upchurch GR Jr, Welch GN, Fabian AJ et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272: 17012-17.
14. Upchurch GR Jr, Welch GN, Fabian AJ, Pigazzi A, Keaney JF Jr, Loscalzo J. Stimulation of endothelial nitric oxide production by homocyst(e)ine. Atherosclerosis 1997; 132: 177-85.
15. Stamler JS, Osborne JA, Jaraki O et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-18.
16. Demuth K, Atger V, Borderie D et al. Homocysteine decreases endothelin-1 production by cultured human endothelial cells. Eur J Biochem 1999; 263: 367-76.
17. Pfanzagl B, Trib IF, Koller E, Moslinger T. Homocysteine strongly enhances metal-catalyzed LDL oxidation in the presence of cystine and cysteine. Atherosclerosis 2003; 168: 39-48.
18. O K, Lynn EG, Chung YH, Siow YL, Man RY, Choy PC. Homocysteine stimulates the production and secretion of cholesterol in hepatic cells. Biochim Biophys Acta 1998; 1393: 317-24.
19. Lentz SR, Sadler JE. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 1993; 81: 683-89.
20. Outinen PA, Sood SK, Pfeifer SI et al. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood 1999; 94: 959-67.
21. Lang D, Kredan MB, Moat SJ et al. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions. Arterioscler Thromb Vasc Biol 2000; 20: 422-27.
22. Zhang F, Slungaard A, Vercellotti GM, Iadecola C. Superoxide-dependent cerebrovascular effects of homocysteine. Am J Physiol 1998; 274: R1704-11.
23. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 5-7.
24. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. Faseb J 1999; 13: 2277-83.
25. Hultberg B, Andersson A, Isaksson A. Hypomethylation as a cause of homocysteine-induced cell damage in human cell lines. Toxicology 2000; 147: 69-75.
26. Duan J, Murohara T, Ikeda H et al. Hypercholesterolemia inhibits angiogenesis in response to hindlimb ischemia: nitric oxide-dependent mechanism. Circulation 2000; 102 (19 Suppl. 3): III370-76.
27. Nagai Y, Tasaki H, Takatsu H et al. Homocysteine inhibits angiogenesis in vitro and in vivo. Biochem Biophys Res Commun 2001; 281: 726-31.
28. Rivard A, Fabre J-E, Silver M et al. Age-dependent impairment of angiogenesis. Circulation 1999; 99: 111-20.
29. -/- mice. Circulation 1999; 99: 3188-98.
30. Rivard A, Silver M, Chen D et al. Rescue of diabetes related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999; 154: 355-64.
31. Watanabe M, Osada J, Aratani Y et al. Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocysteinemia. Proc Natl Acad Sci U S A 1995; 92: 1585-89.
32. Malinow MR, Kang SS, Taylor LM et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989; 79: 1180-88.
33. Couffinhal T, Silver M, Zheng LP, Kearney M, Witzenbichler B, Isner JM. Mouse model of angiogenesis. Am J Pathol 1998; 152: 1667-79.
34. Kawamoto A, Murayama T, Kusano K et al. Synergistic effect of bone marrow mobilization and vascular endothelial growth factor-2 gene therapy in myocardial ischemia. Circulation 2004; 110: 1398-405.
35. Kureishi Y, Luo Z, Shiojima I. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004-10.
36. Llevadot J, Murasawa S, Kureishi Y et al. HMG-CoA reductase inhibitor mobilizes bone-marrow derived endothelial progenitor cells. J Clin Invest 2001; 108: 399-405.
37. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95.
38. Liu W, Ahmad SA, Reinmuth N et al. Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis 2000; 5: 323-28.
39. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization (Perspective). J Clin Invest 1999; 103: 1231-36.
40. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002; 29: 10-14.
41. Losordo DW, Vale PR, Isner JM. Gene therapy for myocardial angiogenesis. Am Heart J 1999; 138: S132-41.
42. Isner JM, Ropper A, Hirst K. VEGF gene transfer for diabetic neuropathy. Hum Gene Ther 2001; 12: 1593-94.
43. Glade-Bender J, Kandel JJ, Yamashiro DJ. VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 2003; 3: 263-76.
44. Duan J, Murohara T, Ikeda H et al. Hyperhomocysteinemia impairs angiogenesis in response to hindlimb ischemia. Arterioscler Thromb Vasc Biol 2000; 20: 2579-85.
45. Nagai Y, Tasaki H, Miyamoto M et al. Plasma level of homocysteine is inversely-associated with the development of collateral circulation in patients with single-vessel coronary artery disease. Circ J 2002; 66: 158-62.
46. Gerber HP, McMurtrey A, Kowalski J et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30 336-43.
47. Dimmeler S, Zeiher AM. Akt takes center stage in angiogenesis signaling. Circ Res 2000; 86: 4-5.
48. Heydrick SJ, Weiss N, Thomas SR et al. L-Homocysteine and L-homocystine stereospecifically induce endothelial nitric oxide synthase-dependent lipid peroxidation in endothelial cells. Free Radic Biol Med 2004; 36: 632-40.
49. Fulton D, Gratton JP, McCabe TJ et al. Regulation of endothelium-derived nitric oxide production by the protein kinase akt. Nature 1999; 399: 597-601.
50. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 2002; 90: 1243-50.
51. Morales-Ruiz M, Fulton D, Sowa G et al. Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase akt. Circ Res 2000; 86: 892-96.
52. Fujio Y, Walsh K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 1999; 274: 16 439-54.
53. Xu D, Neville R, Finkel T. Homocysteine accelerates endothelial cell senescence. FEBS Lett 2000; 470: 20-24.
54. Kang SS, Kwon T, Kwon DY, Do SI. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 1999; 274: 13 085-90.